Aim immunotech announces phase 2a human challenge trial to test its drug ampligen as an intranasal antiviral prophylactic therapy

Subjects will be exposed under controlled clinical facilities and medical monitoring to a/perth/16/2009 (h3n2) or human rhinovirus (hrv-16) to gauge ampligen's effectiveness against those, and potentially other viruses subjects will be exposed under controlled clinical facilities and medical monitoring to a/perth/16/2009 (h3n2) or human rhinovirus (hrv-16) to gauge ampligen's effectiveness against those, and potentially other viruses
AIM Ratings Summary
AIM Quant Ranking